Persistent Systems Launches GenMolVS With NVIDIA Support
Persistent Systems on March 17, 2026 announced a collaboration with NVIDIA to develop GenMolVS, a Generative Molecules and Virtual Screening solution powered by NVIDIA BioNeMo and NeMo Agent Toolkit. The platform uses AI-driven molecular simulations and NVIDIA AI Enterprise components to enable virtual screening and candidate prioritization, aiming to compress months-long drug discovery timelines into days for biopharma clients.
Key Points
- 1Announces GenMolVS using NVIDIA BioNeMo and NeMo Agent Toolkit for AI-driven molecular simulations
- 2States goal to compress months-long drug discovery timelines to days, reducing early-stage experimental risk
- 3Enables biopharma teams to prioritize candidates virtually, lowering wet-lab costs and accelerating development
Scoring Rationale
Official NVIDIA-Persistent collaboration enables production-grade molecular simulation, but impact remains sector-focused rather than broadly transformative.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
